Pharma Mar SA
Carmen joined PharmaMar in 1997 performing in different positions in the R&D Department. In 2003, she was appointed Director of Research & Development at PharmaMar, where she is responsible for the areas of drug discovery, medicinal chemistry and preclinical. Carmen has authored more than 85 scientific publications and has been invited to speak numerous times at international scientific congresses and research institutions. She has an impressive record in drug discovery, with over 20 patent applications and more than 20 funded research programs. Among other achievements, she is responsible for the development of the innovative synthesis process of the marine-derived anticancer drug, Yondelis. Carmen obtained her Ph.D. in Chemistry from the University of the Basque Country, and completed her post-doctoral training at the School of Medicine at the University of Alcala de Henares in Madrid, working within the Pharmacology Department. She also obtained a management development program diploma from IESE.
This person is not in any offices
Pharma Mar SA
Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical diseases areas. It manufactures and sells Yondelis, a synthetically modified antitumor agent, which is derived from sea squirts and is implemented in the treatment of soft tissue sarcomas and relapsed ovarian cancer. Furthermore, the Company's products pipeline comprises drug candidates and agents for cancer treatment, such as Aplidin, PM01183 and PM060184. The Company operates through subsidiaries in Italy, Germany, France, and the United States, among others.